Transplantation for Patients With Chronic Lymphocytic Leukemia

Stanford University28 enrolled

Overview

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Leukemia, Lymphocytic, Chronic

Interventions

high dose chemotherapy then autologous hematopoietic cell transplantPROCEDURE

ablative allogeneic hematopoietic cell transplantPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria:- adequate organ function * normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease * For autologous patients more than 30% bone marrow involvement

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Efficacy

Secondary Outcomes

Feasibility

Toxicity

olymerase Chain Reaction (PCR) for minimal residual disease

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.